Rhythm Pharmaceuticals, Inc.
(NASDAQ : RYTM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
2.44%289.531.4%$864.08m
CELGCelgene Corp.
-1.13%108.091.3%$560.83m
AMGNAmgen, Inc.
1.05%222.991.3%$532.95m
GILDGilead Sciences, Inc.
0.76%64.781.0%$395.21m
VRTXVertex Pharmaceuticals, Inc.
2.07%214.341.9%$329.28m
ILMNIllumina, Inc.
1.55%311.413.5%$329.05m
REGNRegeneron Pharmaceuticals, Inc.
0.69%342.542.6%$272.44m
EXASEXACT Sciences Corp.
2.87%84.5224.0%$224.65m
ALXNAlexion Pharmaceuticals, Inc.
2.07%110.202.0%$183.12m
SGENSeattle Genetics, Inc.
1.55%117.526.1%$143.05m
BMRNBioMarin Pharmaceutical, Inc.
2.26%76.874.3%$129.75m
SRPTSarepta Therapeutics, Inc.
0.01%97.9114.6%$118.57m
AAgilent Technologies, Inc.
1.50%79.111.6%$99.54m
BGNEBeiGene Ltd.
2.61%201.122.1%$92.73m
NBIXNeurocrine Biosciences, Inc.
-0.55%114.025.0%$87.66m

Company Profile

Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.